Dr. Roach: Providing more information about Repatha for cholesterol

I felt that it just wasn't worth all the aches and pains.
Tribune Chronicle

Repatha for cholesterol

I’m a 75-year-old woman who’s in very good health. Since my early 50s, I’ve had issues with my cholesterol. My ...
Nasdaq

REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to ...
Investor's Business Daily on MSN

Amgen's numbers are out: It gets to keep its cholesterol crown — for now

Amgen widely beat the Street's first-quarter expectations late Thursday, slightly ticking its 2026 guidance higher.
KXAN

AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.

THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha ® (evolocumab). This follows ...
Seeking Alpha

AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025

Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...
Fierce Pharma

Repatha sales help Amgen overcome Prolia biosimilar hits in 1st quarter

Amgen CEO Robert Bradway has declared 2026 a “springboard year” for the California big biotech, in which the growth of its ...
KVOA 4

REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS

Repatha was first approved in 2015 and has since been used by more than 8 million patients globally. 5,6 In August 2025, the U.S. Food and Drug Administration broadened the approved use of Repatha to ...
Nasdaq

REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS

Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha ...